Výsledky vyhledávání - "Anne Borgman"

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer

Autor: Hidehito Horinouchi, Noboru Yamamoto, Tomohide Tamura, Atsushi Horiike, Hiroshi Nokihara, Anne Borgman, Makoto Nishio, Yifah Yaron, Yutaka Fujiwara, Noriko Yanagitani, Fumiyoshi Ohyanagi, Shintaro Kanda, Linh Nguyen

Publikováno v: Clinical lung cancer. 20(3)

Background Cabozantinib inhibits tyrosine kinases including MET, AXL, VEGFR2, RET, KIT, and ROS1 and has demonstrated antitumor activity in multiple tumor types. The primary objective of this phase 1 study ( NCT01553656 ) was to determine the maximum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bdef7f660ed0437382d13eaeebe9229
https://pubmed.ncbi.nlm.nih.gov/30718102

Zobrazit plný text záznamu

Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Autor: R. Sinha, Anne Borgman, Lorenza Rimassa, Fawzi Benzaghou, Fadi Braiteh, S. Hazra, Robin Katie Kelley, A-L Cheng, Andrew X. Zhu, Z. Kayali

Publikováno v: Annals of Oncology. 30:iv65-iv66

Background C inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER). C is approved in the United States and Europe for treatment of aHCC after prior S based on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::93814d029436a0b6326eea8ce05c833b
https://doi.org/10.1093/annonc/mdz155.237

Zobrazit plný text záznamu

A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy

Autor: Candy Bermingham, Anne Borgman, Marcia S. Brose, Soham Puvvada, Bruce G. Robinson, Jaume Capdevila, Monika K. Krzyzanowska, Steven I. Sherman

Publikováno v: Journal of Clinical Oncology. 37:TPS6097-TPS6097

TPS6097 Background: Treatment options are limited for patients with RAI-refractory DTC that is resistant to VEGFR-targeted therapy. Cabozantinib inhibits receptor tyrosine kinases including VEGFR2, MET, AXL, and RET, which are implicated in the devel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::011aaed3f1a8578ccf8dc5f720c071bb
https://doi.org/10.1200/jco.2019.37.15_suppl.tps6097

Zobrazit plný text záznamu

Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Autor: Joong-Won Park, Steven Milwee, Ann-Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Fawzi Benzaghou, Anne Borgman, Andrew X. Zhu, Fadi Braiteh, Robin Kate Kelley, Zeid K Kayali

Publikováno v: Journal of Clinical Oncology. 37:TPS4157-TPS4157

TPS4157 Background: C inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER). C is approved for treatment of aHCC after prior S based on improved overall surviv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d0716f27e21f0c5519a2e99fcc418de
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4157

Zobrazit plný text záznamu

A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)

Autor: Martin Schlumberger, Bhumsuk Keam, R. Elisei, Hui K Gan, A. Klochikhin, Ellen Kapiteijn, Jaume Capdevila, J. Partyka, Anne Borgman, Jolanta Krajewska, Bruce G. Robinson

Publikováno v: Annals of Oncology. 29:viii647-viii648

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5f7699c2b41bdbbb0b41d3b20c704b8d
https://doi.org/10.1093/annonc/mdy302.009

Zobrazit plný text záznamu

Abstract B179: Final results of a phase 1 study of cabozantinib (Cabo) in Japanese patients (pts) with expansion cohorts in non-small cell lung cancer (NSCLC) with defined molecular alterations

Autor: Yutaka Fujiwawa, Noboru Yamamoto, Fumiyoshi Ohyanagi, Hiroshi Nokihara, Anne Borgman, Shintaro Kanda, Asushi Horiike, Makoto Nishio, Yifah Yaron, Hidehito Horinouchi, Tomohide Tamura

Publikováno v: Molecular Cancer Therapeutics. 14:B179-B179

Background: Cabo inhibits tyrosine kinases including MET, VEGF receptors, AXL, and RET. The primary objective of this phase 1 study was to establish the recommended phase 2 dose (RP2D) of Cabo in Japanese pts; secondary objectives included assessment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a6e61920a3d07da6b2cd8f971749d29
https://doi.org/10.1158/1535-7163.targ-15-b179

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání